| Followers | 21 |
| Posts | 946 |
| Boards Moderated | 0 |
| Alias Born | 07/20/2020 |
Monday, May 03, 2021 5:32:39 PM
Yes, indeed today's news is very good. No surprise with the share price as people want to see that it works. Clearly, it does. This is what SeptMike was talking about last July. We achieved expanded access program (compassionate news) last year to be used in severe cases, but nothing ever transpired. It appears the results for mild/moderate are good and Revive is looking to build up its portfolio by expanding to severe cases. It would be cool if a doctor prescribed it for a severe case and the patient recovered. We have been waiting for that news for quite some time.
ps. I totally get the frustration with the men who do not want to sit around for a long study, but that is not going to stop MF from applying for EUA before the completion of the trial. All this does is make us stronger. All is good. We wait.
ps. I totally get the frustration with the men who do not want to sit around for a long study, but that is not going to stop MF from applying for EUA before the completion of the trial. All this does is make us stronger. All is good. We wait.
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
